137 related articles for article (PubMed ID: 11299783)
1. Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Osmak M; Svetić B; Gabrijelcić-Geiger D; Skrk J
Anticancer Res; 2001; 21(1A):481-3. PubMed ID: 11299783
[TBL] [Abstract][Full Text] [Related]
2. Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L.
Fröhlich E; Möhrle M; Klessen C
Arch Dermatol Res; 2004 Mar; 295(10):411-21. PubMed ID: 14767779
[TBL] [Abstract][Full Text] [Related]
3. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
Friedrich B; Jung K; Lein M; Türk I; Rudolph B; Hampel G; Schnorr D; Loening SA
Eur J Cancer; 1999 Jan; 35(1):138-44. PubMed ID: 10211102
[TBL] [Abstract][Full Text] [Related]
4. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
5. Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance.
Jung K; Friedrich B; Türk I; Roigas J; Lein M; Schnorr D; Loening SA
J Cancer Res Clin Oncol; 1998 Jan; 124(1):60-1. PubMed ID: 9498837
[No Abstract] [Full Text] [Related]
6. Determination of cathepsins B, H, L and kininogen in breast cancer patients.
Gabrijelcic D; Svetic B; Spaić D; Skrk J; Budihna J; Turk V
Agents Actions Suppl; 1992; 38 ( Pt 2)():350-7. PubMed ID: 1334335
[TBL] [Abstract][Full Text] [Related]
7. Proteases as prognostic markers in cancer.
Duffy MJ
Clin Cancer Res; 1996 Apr; 2(4):613-8. PubMed ID: 9816210
[TBL] [Abstract][Full Text] [Related]
8. Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease.
Azaryan AV; Hook VY
Arch Biochem Biophys; 1994 Oct; 314(1):171-7. PubMed ID: 7944391
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
10. Cathepsins B, H and L in human breast carcinoma.
Gabrijelcic D; Svetic B; Spaić D; Skrk J; Budihna M; Dolenc I; Popovic T; Cotic V; Turk V
Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):69-74. PubMed ID: 1316176
[TBL] [Abstract][Full Text] [Related]
11. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal cysteine proteinases in rat epididymis.
Tomomasa H; Waguri S; Umeda T; Koiso K; Kominami E; Uchiyama Y
J Histochem Cytochem; 1994 Mar; 42(3):417-25. PubMed ID: 8308258
[TBL] [Abstract][Full Text] [Related]
13. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma.
Dohchin A; Suzuki JI; Seki H; Masutani M; Shiroto H; Kawakami Y
Cancer; 2000 Aug; 89(3):482-7. PubMed ID: 10931446
[TBL] [Abstract][Full Text] [Related]
14. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Cardin R; Di Mario F; Kusstatscher S; Naccarato R; Farinati F
Am J Gastroenterol; 1997 May; 92(5):843-7. PubMed ID: 9149198
[TBL] [Abstract][Full Text] [Related]
15. Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines.
Maciewicz RA; Wardale RJ; Etherington DJ; Paraskeva C
Int J Cancer; 1989 Mar; 43(3):478-86. PubMed ID: 2647640
[TBL] [Abstract][Full Text] [Related]
16. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase.
Ikeda Y; Ikata T; Mishiro T; Nakano S; Ikebe M; Yasuoka S
J Med Invest; 2000 Feb; 47(1-2):61-75. PubMed ID: 10740981
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64.
Navab R; Mort JS; Brodt P
Clin Exp Metastasis; 1997 Mar; 15(2):121-9. PubMed ID: 9062388
[TBL] [Abstract][Full Text] [Related]
19. Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver.
Yamamoto H; Murawaki Y; Kawasaki H
Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):95-112. PubMed ID: 1518964
[TBL] [Abstract][Full Text] [Related]
20. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion.
Cuvier C; Jang A; Hill RP
Clin Exp Metastasis; 1997 Jan; 15(1):19-25. PubMed ID: 9009102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
